Cover Image
市場調查報告書

高容量穿戴式注射器市場

Large Volume Wearable Injectors Market (3rd Edition), 2017-2027

出版商 ROOTS ANALYSIS 商品編碼 312919
出版日期 內容資訊 英文 365 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
高容量穿戴式注射器市場 Large Volume Wearable Injectors Market (3rd Edition), 2017-2027
出版日期: 2017年01月31日 內容資訊: 英文 365 Pages
簡介

本報告提供高容量穿戴式注射器市場相關調查分析,以目前的市場情勢與未來預測為焦點之系統性資訊。

第1章 序文

第2章 摘要整理

第3章 簡介

第4章 高容量穿戴式注射器:市場形勢

  • 概要
  • 整體開發形勢
  • 非胰島素生技藥品開發形勢
  • 胰島素開發形勢
  • 分佈:各地區

第5章 產品競爭力,臨床設計,專利分析

  • 概要
  • 產品競爭力分析
  • 電網分析
  • 專利分析

第6章 非胰島素生技藥品高容量穿戴式注射器:設備簡介

  • 概要
  • eLVD Patch Pump (Elcam Drug Delivery Devices (E3D))
  • Enable Injector (Enable Injections)
  • Lapas (Bespak)
  • BD Libertas Wearable Injector (Becton Dickinson)
  • PatchPump (SteadyMed Therapeutics)
  • Precision-Therapy Wearable Injector,Flex-Therapy Wearable Injector,Flex-Therapy Mini Wearable Injector (Unilife Corporation)
  • sc2 Wear Infusor (scPharmaceuticals)
  • 拋棄式注入設備 (Roche)
  • SenseBolus,SensePatch,SenseTrial (Sensile Medical)
  • SmartDose Electronic Wearable Injector (West Pharmaceutical Services)

第7章 胰島素高容量穿戴式注射器:設備簡介

  • 概要
  • 糖尿病:簡介
  • 先進胰島素遞送系統:設備簡介
  • 胰島素高容量穿戴式注射器:趨勢與社群媒體

第8章 案例研究:評估中的藥物和設備的組合

  • 概要
  • Repatha/Evolocumab/AMG 145
  • Treprostinil
  • Furosemide
  • Herceptin
  • ND0612/Levadopa,Carbidopa
  • ND0701/Apomorphine
  • SMT-201/Ketorolac
  • Ceftriaxone

第9章 高容量穿戴式注射器的標的生技藥品

  • 概要
  • 已上市生技藥品
  • 開發平台分子

第10章 與市場預測機會分析

  • 概要
  • 預測手法
  • 主要的前提條件
  • 預測

第11章 主要企業

  • 概要
  • Becton Dickinson
  • CeQur
  • Debiotech
  • Insulet Corporation
  • Roche Laboratories
  • Sensile Medical
  • SteadyMed Therapeutics
  • Tandem Diabetes Care
  • Unilife Corporation
  • West Pharmaceutical Services

第12章 SWOT分析

第13章 結論

第14章 採訪

第15章 附錄1

第16章 附錄2

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: RA10075

Drug delivery systems optimized to provide flexibility in dosing regimen, reduce the number of hospital visits, decrease dependence on healthcare professionals and enhance adherence to the therapeutic regimen have become the preferred choice of drug administration. The large scale adoption of prefilled syringes, the first ready-to-use injection device to be marketed, demonstrated the growing interest in the concept of such convenient drug delivery systems. In addition, several pen-injectors and autoinjectors have witnessed an impressive growth in the recent past. However, these hand-held devices are only capable of administering drugs with dosing volume close to 1 ml. With over 900 biologics being developed (most of these are highly viscous and are required to be delivered in volumes greater than 1 ml), there is a growing demand for self-administration devices than can overcome this unmet need.

Large volume wearable injectors, an advanced version of the existing self-injection devices, are expected to gather interest from a wide customer base. In fact, there are a number of such injectors commercially available for delivery of insulin. OmniPod, from Insulet Corporation, is a very well-known device that has generated significant year-on-year revenue growth. However, it is worth highlighting that till date only one large volume wearable injector (SmartDose Electronic Wearable Injector) has been approved for administration of a non-insulin biologic. Despite the uncertainties related to the device development and approval, many companies are investing their time, money and resources to develop these novel devices. In addition to the publically known programs, pharma companies have many undisclosed programs that are likely to provide the necessary growth impetus in the long term.

It is worth noting that the VC community has demonstrated significant interest in funding projects related to such wearable injectors. These investments are expected to drive further innovation and lead to the introduction of novel device candidates in the industry. Quite recently, in January 2017, scPharmaceuticals closed a series B investment round worth USD 45.6 million. The company intends to use the funding to bring Furoscix and the sc2Wear Infusor to the market in the US. Earlier, in July 2016, SteadyMed Therapeutics raised USD 32 million in a private placement round financed by Deerfield Capital Management, Federated Investors and OrbiMed. In September 2015, CeQur completed a USD 100 million Venture (Series C) financing round, which was led by Woodford Investment Management, Arthurian Life Sciences, Endeavour Vision, VI Partners and Schroders.

Several partnerships have also been inked in this domain in the last few years. Most of these are focused on the development / commercialization of a variety of wearable injectors. Such partnerships are important for technological integration, supply of devices and also facilitate the conduct of clinical trials related to drug-device combination products. We believe that the device developers will continue to strive to introduce unique and user-friendly features into their proprietary range of devices. The upgradation of existing devices to more competent / next generation devices will serve as a key driver of immediate near-term growth.

Synopsis:

The “Large Volume Wearable Injectors Market (3rd Edition), 2017-2027” report features an extensive study of the current landscape and the likely future evolution of this category of drug delivery devices over the next ten years. With the increasing incidence of chronic and lifestyle-related diseases across the globe, the demand for efficient drug delivery systems is growing at a rapid pace. In order to simplify the process of drug delivery, eliminate costs and reduce the incidence of needlestick injuries, the pharmaceutical industry has shifted its focus towards the development of self-injection devices for parenteral drugs / therapies. This report specifically lays emphasis on the emergence of such patient-centric, convenient, cost-effective and user-friendly wearable injectors that are capable of administering large volumes of a drug subcutaneously in a home-care setting.

It is worth noting that the concept behind such injectors is being widely employed for the delivery of insulin. Over 15 such unique series of injectors (excluding variants) have already entered the market. On the other hand, there is only one large volume wearable injector (mentioned above) approved for the administration of a non-insulin biologic in the US. However, with a variety of biologics under investigation, we believe that device developers have a significant opportunity waiting to be tapped. The field is likely to pick up momentum in the next few years. In fact, an increase in the partnerships and investment activities demonstrate that the market is geared towards significant growth in the mid to long term.

One of the key objectives outlined for the study was to evaluate the future potential of the ongoing development programs of both big and small firms. Amongst other elements, the report elaborates on the following areas:

  • An overview of the current market landscape in terms of the key players involved, development status of pipeline products (marketed / under development), type of dose (bolus / continuous / both), usability (disposable / reusable) and key indications.
  • Detailed profiles of large volume wearable devices that are being developed for the delivery of biologics (including insulin), highlighting their key features, current status of development, recent developments and associated collaborations.
  • An exhaustive review of over 300 biologics, which are potential candidates for delivery using large volume wearable injectors. The molecules / therapies have been categorized into most-likely, likely and less-likely candidates for administration using large volume wearable injectors. This categorization is based on various parameters including recommended volume, route of administration, frequency of the dose, standard / weight based dose and the chronicity of target indication.
  • Comprehensive case studies on drugs that are being evaluated for delivery via large volume wearable injectors, highlighting their specifications, mechanisms of action, current status of development, sales, respective dosages and any other recent developments.
  • An illustrative grid representation of the devices based on the category of device (insulin / non-insulin biologic), type of dose and type of device (infusion pump / patch pump). In addition, the report includes an insightful 2 X 2 matrix analysis, highlighting the positioning of the devices based on product competitiveness and supplier power.
  • A discussion on the key drivers and challenges, in terms of the strengths, weaknesses, opportunities and threats (SWOT), which are likely to impact the future growth of this upcoming area.

The study provides a detailed market forecast and opportunity analysis for the period between 2017 and 2027. The research, analysis and insights presented in this report include potential sales of the drug-device combinations that are being evaluated and are anticipated to enter the market in the next few years. To add robustness to our model, we have provided three market forecast scenarios, namely the conservative, base and optimistic scenarios. It is worth noting that, although the market of insulin delivery devices is relatively more mature, we have included a high-level opportunity analysis on the large volume wearable injectors being developed for delivery of insulin as well.

Our opinions and insights presented in this study were influenced by discussions conducted with several experts in this area. Specifically, we solicited the opinions of senior representatives including Menachem Zucker (VP and Chief Scientist, Elcam Medical), Michael Hooven (CEO, Enable Injections), Ben Moga (President, Ratio Drug Delivery), Pieter Muntendam (President and CEO, scPharmaceuticals), Graham Reynolds, (VP and GM, Biologics, West Pharmaceutical Services) and Tiffany H. Burke (Director, Global Communications, West Pharmaceutical Services). All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. The financial figures mentioned in this report are in USD, unless otherwise specified.

Example Highlights:

  • 1. There are over 50 different large volume wearable injectors (including variants) that are either commercialized or are under development. Of these, around 60% are for delivery of insulin and the rest are for delivery of other biologics. Of the devices being developed for delivery of non-insulin biologics, SmartDose Electronic Wearable Injector (by West Pharmaceutical Services) has already received approval by the USFDA for delivery of Repatha.
  • 2. There are several other known references of drug-device combinations that are being evaluated in clinical studies; examples include SteadyMed Therapeutics' PatchPump (with Treprostinil and Ketorolac), NeuroDerm's CRONO ND (with NDO612 and NDO712), Roche's Single-use injection device (with Herceptin) and scPharmaceuticals's scWear Infusor (with Ceftriaxone and Furosemide).
  • 3. The commercially available insulin-based large volume wearable injectors can accommodate volumes of up to 5 ml. OmniPod, from Insulet Corporation, is a very well-known device that has generated significant year-on-year revenue growth. However, with improved design, several devices with capacity of holding up to 20 ml drug are being developed for delivery of biologics. In fact, over 50% of the devices that we identified for administration of non-insulin biologics have the capability of carrying 5-20 ml drug while 16% of these devices can hold over 20 ml drug.
  • 4. Our analysis suggests that close to 100 biologics (marketed / under development) are suited for delivery via large volume wearable injectors and are likely to be evaluated in different drug-device combinations in the near future. These biologics (full list available in the main report) are designed for treatment of chronic conditions, which require frequent dosing, and are not currently available in suitable self-administration systems. We believe that some of these drugs, if tested and approved with large volume wearable injectors, are likely to make a substantial contribution to the market's evolution in the mid-long term.
  • 5. Innovation in the field is primarily being driven by start-ups / small companies; examples of firms working for delivery of non-insulin biologics include (in alphabetical order) Elcam Drug Delivery Systems, Enable Injections, NeuroDerm, scPharmaceuticals, Sensile Medical. Notable examples of start-ups that have taken initiatives for delivery of insulin include Cellnovo, CeQur, Debiotech, PicoSulin, SOOIL and ViCentra. In addition, a number of large companies are making notable contribution in this field; prominent players include Becton Dickinson, Johnson & Johnson, Medtronic, Roche and West Pharmaceutical Services.
  • 6. Several other companies engaged in this domain have reported positive clinical outcomes of their drug-device combinations. scPharmaceuticals is expecting the commercial launch of its two product candidates for the drugs furosemide and cephalosporin in 2017 / 18. In addition, Neuroderm and SteadyMed Therapeutics are also hopeful of making their products commercially available in the near future. At the same time, insulin delivery devices, such as OmniPod, are now also being explored for the delivery of non-insulin drugs, such as the gonadotropin-releasing hormone developed by Ferring Pharmaceuticals.
  • 7. The overall market for large volume wearable injectors is likely to grow at an aggressive rate of over 150%. We believe that OmniPod will continue to lead the market for insulin delivery. However, majority of the growth is likely to come from drug-device combinations under trials for non-insulin biologics. In our base scenario, we have predicted that the annual sales volume of such devices could be over 40 million units by 2027.

Research Methodology:

Most of the data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information. The secondary sources of information include

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines:

Chapter 2 provides an executive summary of the insights captured in our research. The summary offers a high level view on the likely evolution of the large volume wearable injectors market.

Chapter 3 provides a general introduction to the market and highlights the growing demand for self-administration injection devices. The chapter lays emphasis on the need for such devices driven by the rising incidence of chronic diseases and emergency cases reported per day. Subsequently, it covers the different types of self-injection devices available in the market, highlighting their advantages. This section also features a brief discussion on the concerns related to needlestick injuries and emphasizes the growing preference for safe and easy-to-use devices.

Chapter 4 presents two separate lists of the large volume wearable injectors for insulin and the other biologics. In addition, the chapter includes a detailed analysis of both these lists based on the products' status of development, device category (infusion pump / patch pump), type of dose (bolus / continuous) and the capacity of each device. Specifically for insulin delivery devices, we have identified whether the device is equipped with continuous glucose monitoring (CGM) monitoring or not.

Chapter 5 presents key takeaways from the market landscape of this emerging field. It features a comparison of product competitiveness and supplier power of each device in the form of a 2 x 2 matrix. In addition, the chapter includes a grid based representation of devices based on the target indication, status of development, type of dose (continuous / bolus / both) and type of device (patch pump / infusion pump). The chapter also provides an analysis of the patents granted / filed in this space over the last three years.

Chapter 6 presents detailed profiles on the large volume wearable injectors being developed for biologics / drugs other than insulin. The profiles include information about the developer of the device, device specifications and features, advantages, current status of development and related collaborations. We have presented such insights on 10 devices capable of delivering large dosage volumes.

Chapter 7 is focused on the devices developed / being developed for the administration of insulin. It presents information on diabetes, the most popular target indication, including information on its epidemiology and the evolution of insulin-delivery systems. Additionally, it includes detailed profiles on some of the large volume wearable devices developed / being developed for the delivery of insulin. Each profile covers information on the device developer, device specifications, advantages and the associated developments. The chapter also includes a social media analysis highlighting the popularity of these devices in the industry.

Chapter 8 provides detailed case studies on the drugs / therapies that are currently being evaluated with the devices mentioned in chapter 4. Each case study includes drug / therapy specifications, respective mechanisms of action, current status of development, information on the sales of each product, dosage and recent developments.

Chapter 9 presents a list of candidates (marketed / pipeline) that have the potential to be administered using large volume wearable injectors in the future. The likelihood of delivery of a molecule was estimated based on the volume of dose, mode of administration, frequency of administration, standard / weight-based dose and the chronicity of the target indication.

Chapter 10 provides projections of the future opportunity of the large volume wearable injectors market for biologics till 2027. It highlights the market size of such injectors (in terms of value) and the number of units that are likely to be sold within the forecast time period. We have clearly laid out the forecast methodology along with the key assumptions that were taken into consideration for estimating the market size.

Chapter 11 includes comprehensive profiles of the key companies that are active in this market. We have profiled companies (presented in an alphabetical order) developing devices for administration of insulin / other biologics. Each company profile includes a company overview, details on its financial performance, product portfolio and collaborations.

Chapter 12 provides a SWOT analysis, highlighting strategic insights on major factors that have contributed to the growth of the market, while highlighting the weaknesses and threats that are likely to have an impact on its future.

Chapter 13 summarizes the overall report and provides a recap of the key takeaways from the study. It also presents our independent opinion on the future of large volume wearable injectors market based on the research and analysis described in the previous chapters.

Chapter 14 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the insights provided to us by Menachem Zucker (VP and Chief Scientist, Elcam Medical), Michael Hooven (CEO, Enable Injections), Ben Moga (President, Ratio Drug Delivery), Pieter Muntendam (President and CEO, scPharmaceuticals), Graham Reynolds, (VP and GM, Biologics, West Pharmaceutical Services) and Tiffany H. Burke (Director, Global Communications, West Pharmaceutical Services).

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures presented in the report.

Chapter 16 is an appendix, which provides a list of companies and organizations mentioned in this report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Drug Delivery Devices
  • 3.3. Self-Administration: An Emerging Trend
    • 3.3.1. Rising Burden of Chronic Diseases
    • 3.3.2. Need for Immediate Treatment in Emergency Situations
    • 3.3.3. Expansion of Injectable Biologics Pipeline
    • 3.3.4. Systems Available for Self-administration
      • 3.3.4.1. Prefilled Syringes
      • 3.3.4.2. Pen-Injectors
      • 3.3.4.3. Autoinjectors
      • 3.3.4.4. Needle-Free Injectors
      • 3.3.4.5. Large Volume Wearable Injectors
    • 3.3.5. Needlestick Injuries
      • 3.3.5.1. Incidence and Cost Burden
      • 3.3.5.2. Prevention of Needlestick Injuries
      • 3.3.5.3. Government Legislations for the Prevention of Needlestick Injuries
  • 3.4. Advantages and Future Prospects of Self-Injection Systems

4. LARGE VOLUME WEARABLE INJECTORS: MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. Large Volume Wearable Injectors: Overall Development Landscape
  • 4.3. Large Volume Wearable Injectors: Development Landscape for Non-Insulin Biologics
    • 4.3.1. Distribution by Stage of Development
    • 4.3.2. Distribution by Storage Capacity
    • 4.3.3. Distribution by Device Category (Patch Pumps / Infusion Pumps)
    • 4.3.4. Distribution by Type of Dose (Bolus / Continuous)
    • 4.3.5. Distribution by Usability (Disposable / Reusable)
    • 4.3.6. Distribution by Leading Players
  • 4.4. Large Volume Wearable Injectors: Development Landscape for Insulin
    • 4.4.1. Distribution by Stage of Development
    • 4.4.2. Distribution by Device Volume
    • 4.4.3. Distribution by Device Category (Patch Pumps / Infusion Pumps)
    • 4.4.4. Distribution by Usability (Disposable / Reusable)
    • 4.4.5. Distribution by Availability of CGM System
    • 4.4.6. Distribution by Leading Players
  • 4.5. Large Volume Wearable Injectors: Distribution by Geography

5. PRODUCT COMPETITIVENESS, CLINICAL DESIGN AND PATENT ANALYSIS

  • 5.1. Chapter Overview
  • 5.2. Product Competitiveness Analysis
    • 5.2.1. Product Competitiveness Analysis: Large Volume Wearable Injectors for Non-Insulin Biologics
    • 5.2.2. Product Competitiveness Analysis: Large Volume Wearable Injectors for Insulin
  • 5.3. Grid Analysis: Distribution of Large Volume Wearable Injectors Based on Development Phase and Type of Dosage
  • 5.4. Patent Analysis: Large Volume Wearable Injectors, 2013-2016
    • 5.4.1. Distribution by Current Status
    • 5.4.2. Distribution by Year
    • 5.4.3. Distribution by Key Players
    • 5.4.4. Distribution by Regional Approving Authorities
    • 5.4.5. Distribution by the Type of Patent
    • 5.4.6. Distribution by Patent Expiry Year

6. LARGE VOLUME WEARABLE INJECTORS FOR NON-INSULIN BIOLOGICS: DEVICE PROFILES

  • 6.1. Chapter Overview
  • 6.2. eLVD Patch Pump (Elcam Drug Delivery Devices (E3D))
    • 6.2.1. Introduction
    • 6.2.2. Product Description
    • 6.2.3. Advantages
  • 6.3. Enable Injector (Enable Injections)
    • 6.3.1. Introduction
    • 6.3.2. Product Description
    • 6.3.3. Usage
    • 6.3.4. Advantages
    • 6.3.5. Recent Developments
  • 6.4. Lapas® (Bespak)
    • 6.4.1. Introduction
    • 6.4.2. Product Description
    • 6.4.3. Advantages
  • 6.5. BD Libertas™ Wearable Injector (Becton Dickinson)
    • 6.5.1. Introduction
    • 6.5.2. Product Description
    • 6.5.3. Usage
    • 6.5.4. Advantages
  • 6.6. PatchPump® (SteadyMed Therapeutics)
    • 6.6.1. Introduction
    • 6.6.2. Product Description
    • 6.6.3. Usage
    • 6.6.4. Advantages
    • 6.6.5. Recent Developments
  • 6.7. Precision-Therapy™ Wearable Injector, Flex-Therapy™ Wearable Injector and Flex-Therapy™ Mini Wearable Injector (Unilife Corporation)
    • 6.7.1. Introduction
    • 6.7.2. Product Description
    • 6.7.3. Usage
    • 6.7.4. Advantages
    • 6.7.5. Recent Developments
  • 6.8. sc2™Wear Infusor (scPharmaceuticals)
    • 6.8.1. Introduction
    • 6.8.2. Product Description
    • 6.8.3. Advantages
    • 6.8.4. Recent Developments
  • 6.9. Single-use Injection Device (Roche)
    • 6.9.1. Introduction
    • 6.9.2. Product Description
    • 6.9.3. Usage
    • 6.9.4. Advantages
    • 6.9.5. Recent Developments
  • 6.10. SenseBolus, SensePatch and SenseTrial (Sensile Medical)
    • 6.10.1. Introduction
    • 6.10.2. Product Description
    • 6.10.3. Usage
    • 6.10.4. Advantages
    • 6.10.5. Recent Developments
  • 6.11. SmartDose® Electronic Wearable Injector (West Pharmaceutical Services)
    • 6.11.1. Introduction
    • 6.11.2. Product Description
    • 6.11.3. Usage
    • 6.11.4. Advantages
    • 6.11.5. Recent Developments

7. LARGE VOLUME WEARABLE INJECTORS FOR INSULIN: DEVICE PROFILES

  • 7.1. Chapter Overview
  • 7.2. Diabetes: An Introduction
    • 7.2.1. Epidemiology
    • 7.2.2. Available Therapies
    • 7.2.3. Need for Diabetes Management Systems
  • 7.3. Advanced Insulin Delivery Systems: Device Profiles
    • 7.3.1. ACCU-CHEK® (Roche Diagnostics)
      • 7.3.1.1. Introduction
      • 7.3.1.2. Product Information
      • 7.3.1.3. Advantages
      • 7.3.1.4. Recent Developments
    • 7.3.2. DANA Diabecare® Insulin Pumps (SOOIL)
      • 7.3.2.1. Introduction
      • 7.3.2.2. Product Information
      • 7.3.2.3. Advantages
    • 7.3.3. JewelPUMP™ I and JewelPUMP™ II (Debiotech)
      • 7.3.3.1. Introduction
      • 7.3.3.2. Product Information
      • 7.3.3.3. Advantages
      • 7.3.3.4. Recent Developments
    • 7.3.4. MiniMed® 530G (Medtronic)
      • 7.3.4.1. Introduction
      • 7.3.4.2. Product Information
      • 7.3.4.3. Advantages
      • 7.3.4.4. Recent Developments
    • 7.3.5. mylife™ YpsoPump® (Ypsomed)
      • 7.3.5.1. Introduction
      • 7.3.5.2. Product Information
      • 7.3.5.3. Advantages
    • 7.3.6. OmniPod® (Insulet Corporation)
      • 7.3.6.1. Introduction
      • 7.3.6.2. Product Information
      • 7.3.6.3. Advantages
      • 7.3.6.4. Recent Developments
    • 7.3.7. OneTouch Via™ (Johnson & Johnson)
      • 7.3.7.1. Introduction
      • 7.3.7.2. Product Information
      • 7.3.7.3. Usage
      • 7.3.7.4. Advantages
    • 7.3.8. PAQ™ (CeQur)
      • 7.3.8.1. Introduction
      • 7.3.8.2. Product Information
      • 7.3.8.3. Usage
      • 7.3.8.4. Advantages
      • 7.3.8.5. Recent Developments
    • 7.3.9. t:flex® (Tandem Diabetes Care)
      • 7.3.9.1. Introduction
      • 7.3.9.2. Product Information
      • 7.3.9.3. Advantages
      • 7.3.9.4. Recent Developments
  • 7.4. Large Volume Wearable Injectors for Insulin: Trends on Social Media
    • 7.4.1. Large Volume Wearable Injectors for Insulin: Twitter Trends
    • 7.4.2. Large Volume Wearable Injectors for Insulin: Device Recalls
    • 7.4.3. Large Volume Wearable Injectors for Insulin: Popularity of Continuous Glucose Monitoring

8. CASE STUDIES: DRUG-DEVICE COMBINATIONS UNDER EVALUATION

  • 8.1. Chapter Overview
  • 8.2. Repatha® / Evolocumab / AMG 145
    • 8.2.1. Drug Specifications
    • 8.2.2. Mechanism of Action
    • 8.2.3. Development History
    • 8.2.4. Current Status of Development
    • 8.2.5. Dosage and Sales Information
  • 8.3. Treprostinil
    • 8.3.1. Drug Specifications
    • 8.3.2. Mechanism of Action
    • 8.3.3. Development History
    • 8.3.4. Current Status of Development
    • 8.3.5. Dosage and Sales Information
  • 8.4. Furosemide
    • 8.4.1. Drug Specifications
    • 8.4.2. Mechanism of Action
    • 8.4.3. Development History
    • 8.4.4. Current Status of Development
    • 8.4.5. Dosage and Sales Information
  • 8.5. Herceptin®
    • 8.5.1. Drug Specifications
    • 8.5.2. Mechanism of Action
    • 8.5.3. Development History
    • 8.5.4. Current Status of Development
    • 8.5.5. Dosage and Sales Information
  • 8.6. ND0612 / Levadopa and Carbidopa
    • 8.6.1. Drug Specifications
    • 8.6.2. Mechanism of Action
    • 8.6.3. Development History
    • 8.6.4. Current Status of Development
    • 8.6.5. Dosage and Sales Information
  • 8.7. ND0701 / Apomorphine
    • 8.7.1. Drug Specifications
    • 8.7.2. Mechanism of Action
    • 8.7.3. Current Status of Development
    • 8.7.4. Dosage and Sales Information
  • 8.8. SMT-201 / Ketorolac
    • 8.8.1. Drug Specifications
    • 8.8.2. Mechanism of Action
    • 8.8.3. Development History
    • 8.8.4. Current Status of Development
    • 8.8.5. Dosage and Sales Information
  • 8.9. Ceftriaxone
    • 8.9.1. Drug Specifications
    • 8.9.2. Mechanism of Action
    • 8.9.3. Development History
    • 8.9.4. Current Status of Development
    • 8.9.5. Dosage and Sales Information

9. TARGET BIOLOGICS FOR LARGE VOLUME WEARABLE INJECTORS

  • 9.1. Chapter Overview
  • 9.2. Marketed Biologics
    • 9.2.1. Marketed Biologics: Most Likely Candidates for Administration with Large Volume Wearable Injectors
    • 9.2.2. Marketed Biologics: Likely Candidates for Administration with Large Volume Wearable Injectors
    • 9.2.3. Marketed Biologics: Less Likely Candidates for Administration with Large Volume Wearable Injectors
  • 9.3. Pipeline Molecules
    • 9.3.1. Pipeline Molecules: Most Likely Candidates for Administration with Large Volume Wearable Injectors
    • 9.3.2. Pipeline Molecules: Likely Candidates for Administration with Large Volume Wearable Injectors
    • 9.3.3. Pipeline Molecules: Less Likely Candidates for Administration with Large Volume Wearable Injectors

10. MARKET FORECAST AND OPPORTUNITY ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Forecast Methodology
  • 10.3. Key Assumptions
  • 10.4. Forecast Output
    • 10.4.1. Large Volume Wearable Injectors Market for Non-Insulin Biologics, 2017-2027
    • 10.4.2. Large Volume Wearable Injectors Market for Insulin, 2017-2027

11. LARGE VOLUME WEARABLE INJECTORS: KEY PLAYERS

  • 11.1. Chapter Overview
  • 11.2. Becton Dickinson
    • 11.2.1. Company Overview
    • 11.2.2. Financial Overview
    • 11.2.3. Product Portfolio
    • 11.2.4. Collaborations
    • 11.2.5. Future Outlook
  • 11.3. CeQur
    • 11.3.1. Company Overview
    • 11.3.2. Product Portfolio
    • 11.3.3. Future Outlook
  • 11.4. Debiotech
    • 11.4.1. Company Overview
    • 11.4.2. Product Portfolio
    • 11.4.3. Collaborations
    • 11.4.4. Future Outlook
  • 11.5. Insulet Corporation
    • 11.5.1. Company Overview
    • 11.5.2. Financial Overview
    • 11.5.3. Product Portfolio
    • 11.5.4. Collaborations
    • 11.5.5. Future Outlook
  • 11.6. Roche Laboratories
    • 11.6.1. Company Overview
    • 11.6.2. Financial Overview
    • 11.6.3. Product Portfolio
    • 11.6.4. Collaborations
    • 11.6.5. Future Outlook
  • 11.7. Sensile Medical
    • 11.7.1. Company Overview
    • 11.7.2. Product Portfolio
    • 11.7.3. Collaborations
    • 11.7.4. Future Outlook
  • 11.8. SteadyMed Therapeutics
    • 11.8.1. Company Overview
    • 11.8.2. Financial Overview
    • 11.8.3. Product Portfolio
    • 11.8.4. Collaborations
    • 11.8.5. Future Outlook
  • 11.9. Tandem Diabetes Care
    • 11.9.1. Company Overview
    • 11.9.2. Financial Overview
    • 11.9.3. Product Portfolio
    • 11.9.4. Collaborations
    • 11.9.5. Future Outlook
  • 11.10. Unilife Corporation
    • 11.10.1. Company Overview
    • 11.10.2. Financial Overview
    • 11.10.3. Product Portfolio
    • 11.10.4. Collaborations
    • 11.10.5. Future Outlook
  • 11.11. West Pharmaceutical Services
    • 11.11.1. Company Overview
    • 11.11.2. Financial Overview
    • 11.11.3. Product Portfolio
    • 11.11.4. Collaborations
    • 11.11.5. Future Outlook

12. SWOT ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Strengths
  • 12.3. Weaknesses
  • 12.4. Opportunities
  • 12.5. Threats

13. CONCLUSION

  • 13.1. Novel Drug / Therapy Delivery Solutions Offer a number of Advantages, including Self-Administration in the Home-care Setting
  • 13.2. Technical Improvements have Led to the Development of Advanced Large Volume Wearable Delivery Systems Having Multiple Useful Features
  • 13.3. The Market, Characterized by the Presence of both Large and Small Companies, is Likely to be Impacted by the Growth of the Biologics Market
  • 13.4. Partnerships and Venture Capital Financing have Emerged as Key Drivers of Growth in this Upcoming Area
  • 13.5. The Large Volume Wearable Injector Market is Projected to Grow at an Aggressive Pace Over the Next Decade
  • 13.6. Concluding Remarks

14. INTERVIEW TRANSCRIPTS

  • 14.1. Chapter Overview
  • 14.2. Menachem Zucker, VP and Chief Scientist, Elcam Medical
  • 14.3. Michael Hooven, CEO, Enable Injections
  • 14.4. Ben Moga, President, Ratio Drug Delivery
  • 14.5. Pieter Muntendam, President and CEO, scPharmaceuticals
  • 14.6. Graham Reynolds, VP & GM, Global Biologics and Tiffany H. Burke, Director, Global Communications, West Pharmaceutical Services

15. APPENDIX 1: TABULATED DATA

16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures:

  • Figure 3.1: Types of Drug Delivery Systems
  • Figure 3.2: Types of Self-Injection Devices
  • Figure 3.3: Worldwide Evolution in Healthcare Safety Legislation
  • Figure 4.1: Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Stage of Development
  • Figure 4.2: Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Storage Capacity
  • Figure 4.3: Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Device Category (Patch Pumps / Infusion Pumps)
  • Figure 4.4: Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Type of Dose (Bolus / Continuous)
  • Figure 4.5: Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Usability (Disposable / Reusable)
  • Figure 4.6: Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Leading Players
  • Figure 4.7: Large Volume Wearable Injectors for Insulin: Distribution by Stage of Development
  • Figure 4.8: Large Volume Wearable Injectors for Insulin: Distribution by Device Volume
  • Figure 4.9: Large Volume Wearable Injectors for Insulin: Distribution by Device Category (Patch Pumps / Infusion Pumps)
  • Figure 4.10: Large Volume Wearable Injectors for Insulin: Distribution by Usability (Disposable / Reusable)
  • Figure 4.11: Large Volume Wearable Injectors for Insulin: Distribution by Availability of CGM System
  • Figure 4.12: Large Volume Wearable Injectors for Insulin: Distribution by Leading Players
  • Figure 4.13: Large Volume Wearable Injectors: Distribution by Geography
  • Figure 4.14: Large Volume Wearable Injectors: Regional Landscape
  • Figure 5.1: Product Competitiveness Analysis: Large Volume Wearable Injectors for Non-Insulin Biologics
  • Figure 5.2: Product Competitiveness Analysis: Large Volume Wearable Injectors for Insulin
  • Figure 5.3: Grid Analysis: Distribution by Stage of Development and Type of Dosage
  • Figure 5.4: Patent Analysis: Distribution by Current Status
  • Figure 5.5: Patent Analysis: Distribution by Year
  • Figure 5.6: Patent Analysis: Distribution by Key Players
  • Figure 5.7: Patent Analysis: Distribution by Regional Approving Authorities
  • Figure 5.8: Patent Analysis: Distribution by the Type of Patent
  • Figure 5.9: Patent Analysis: Distribution by Patent Expiry Year
  • Figure 7.1: Diabetes: Worldwide Distribution of the Patients (2015)
  • Figure 7.2: Prevalence of Diabetes: Distribution by Continent (In Million)
  • Figure 7.3: Insulin-Based Therapies for Diabetes
  • Figure 7.4: Non-Insulin Therapies for Diabetes
  • Figure 7.5: Large Volume Wearable Injectors for Insulin: Twitter Trends (2010-2015)
  • Figure 7.6: Large Volume Wearable Injectors for Insulin: Twitter Word Cloud (2010-2015)
  • Figure 7.7: Large Volume Wearable Injectors for Insulin: Device Recalls (2010-2015)
  • Figure 7.8: Large Volume Wearable Injectors for Insulin: Popularity of Continuous Glucose Monitoring
  • Figure 8.1: Treprostinil IV Formulation: Annual Sales 2012 - Q1-Q3 2016 (USD Million)
  • Figure 8.2: Furosemide IV Formulation: Annual Sales, 2013 - Q1-Q3 2016 (EUR Million)
  • Figure 8.3: Herceptin®: Annual Sales, 1999-2015 (CHF Million)
  • Figure 8.4: Levodopa / Carbidopa: Annual Sales, 2010-2015 (USD Million)
  • Figure 8.5: Apokyn®: Annual Sales, 2011-2015 (USD Million)
  • Figure 8.6: Rocephin®: Annual Sales, 2014-2015 (CHF Million)
  • Figure 9.1: Marketed / Under Development Molecules: Parameters and Scoring Criteria
  • Figure 10.1: Large Volume Wearable Injectors Market for Non-Insulin Biologics: Base Scenario, 2017-2027 (USD Million)
  • Figure 10.2: Large Volume Wearable Injectors Market for Non-Insulin Biologics: Base Scenario, Number of Units, 2017-2027 (Million)
  • Figure 10.3: Large Volume Wearable Injectors for Non-Insulin Biologics: Market Evolution 2021-2024-2027 (Million)
  • Figure 10.4: Large Volume Wearable Injectors for Non-Insulin Biologics: Market Share of Devices, 2016, 2020, 2027 (USD Million)
  • Figure 10.5: Large Volume Wearable Injectors Market for Insulin: Base Scenario, 2017-2027 (USD Million)
  • Figure 10.6: Large Volume Wearable Injectors Market for Insulin: Base Scenario, Number of Units, 2017-2027 (Million)
  • Figure 11.1: Becton Dickinson: Annual Revenues, 2011-2016 (USD Billion)
  • Figure 11.2: Insulet Corporation: Annual Revenues, 2011- Q1-Q3 2016 (USD Million)
  • Figure 11.3: Roche: Annual Revenues, 2011 - Q1-Q3 2016 (CHF Million)
  • Figure 11.4: Roche: Annual Revenues, 2016: Distribution by Business Segment (CHF Billion)
  • Figure 11.5: Tandem Diabetes Care: Annual Revenues, 2012 - Q1-Q3 2016 (USD Million)
  • Figure 11.6: Unilife Corporation: Annual Revenues, 2011-2016 (USD Million)
  • Figure 11.7: West Pharmaceutical Services: Annual Revenues, 2011-2016 (USD Million)
  • Figure 13.1: Large Volume Wearable Injectors for Non-Insulin Biologics Market Summary: Number of Units 2017, 2022 and 2027 (Million)

List of Tables:

  • Table 3.1: List of Prefilled Syringes
  • Table 3.2: List of Pen-Injector Systems
  • Table 3.3: List of Autoinjector Systems
  • Table 3.4: List of Needle-Free Injectors
  • Table 4.1: Large Volume Wearable Injectors: Development Landscape for Non-Insulin Biologics
  • Table 4.2: Large Volume Wearable Injectors: Development Landscape for Insulin
  • Table 6.1: Large Volume Wearable Injectors for Non-Insulin Biologics: List of Devices Profiles
  • Table 7.1: Advanced Insulin Delivery Systems
  • Table 7.2: DANA Diabecare®: Specifications
  • Table 7.3: JewelPUMP™: Specifications
  • Table 7.4: JewelPUMP™: Advantages
  • Table 7.5: MiniMed® 530G: Specifications
  • Table 7.6: mylife™ YpsoPump®: Specifications
  • Table 7.7: OmniPod®: Specifications
  • Table 7.8: t:flex®: Specifications
  • Table 8.1: Large Volume Wearable Injectors: Drugs under Evaluation
  • Table 8.2: Repatha®: Clinical Trials
  • Table 8.3: Remodulin®: Dosage Regimen
  • Table 8.4: Orenitram®: Dosage
  • Table 8.5: Tyvaso®: Dosage
  • Table 8.6: Furosemide: Clinical Trials
  • Table 8.7: Furosemide: Manufacturers and Suppliers
  • Table 8.8: Subcutaneous Herceptin®: Clinical Trials
  • Table 8.9: ND0612: Clinical Trials
  • Table 8.10: ND0612H: Phase II Trials (Objectives and Results)
  • Table 8.11: Levodopa / Carbidopa: Manufacturer and Suppliers
  • Table 8.12: Ketorolac Tromethamine: Manufacturers and Suppliers
  • Table 9.1: Marketed Biologics: Most Likely Candidates for Administration with Large Volume Wearable Injectors
  • Table 9.2: Marketed Biologics: Likely Candidates for Administration with Large Volume Wearable Injectors
  • Table 9.3: Marketed Biologics: Less Likely Candidates for Administration with Large Volume Wearable Injectors
  • Table 9.4: Pipeline Molecules: Most Likely Candidates for Administration with Large Volume Wearable Injectors
  • Table 9.5: Pipeline Molecules: Likely Candidates for Administration with Large Volume Wearable Injectors
  • Table 9.6: Pipeline Molecules: Less Likely Candidates for Administration with Large Volume Wearable Injectors
  • Table 10.1: Large Volume Wearable Injectors for Non-Insulin Biologics (Approved / Under Development)
  • Table 11.1: Large Volume Wearable Injectors: Key Players
  • Table 11.2: Becton Dickinson: Medical Devices Portfolio
  • Table 11.3: Debiotech: Medical Devices Portfolio
  • Table 11.4: Sensile Medical: Medical Devices Portfolio
  • Table 11.5: SteadyMed Therapeutics: Medical Devices Portfolio
  • Table 11.6: t:slim X2™ Insulin Pump: Features
  • Table 11.7: t:slim X2™ Insulin Pump: Technical Specifications
  • Table 11.8: t:flex® Insulin Pump: Features
  • Table 11.9: t:flex® Insulin Pump: Technical Specifications
  • Table 11.10 West Pharmaceutical Services: Medical Devices Portfolio
  • Table 12.1: Large Volume Wearable Injectors: SWOT Analysis
  • Table 12.2: Recall of Device (Autoinjectors and Prefilled Syringes)
  • Table 15.1: Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Stage of Development
  • Table 15.2: Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Storage Capacity
  • Table 15.3: Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Device Category (Patch Pumps / Infusion Pumps)
  • Table 15.4: Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Type of Dose (Bolus / Continuous)
  • Table 15.5: Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Usability (Disposable / Reusable)
  • Table 15.6: Large Volume Wearable Injectors for Non-Insulin Biologics: Distribution by Leading Players
  • Table 15.7: Large Volume Wearable Injectors for Insulin: Distribution by Stage of Development
  • Table 15.8: Large Volume Wearable Injectors for Insulin: Distribution by Device Volume
  • Table 15.9: Large Volume Wearable Injectors for Insulin: Distribution by Device Category (Patch Pumps / Infusion Pumps)
  • Table 15.10: Large Volume Wearable Injectors for Insulin: Distribution by Usability (Disposable / Reusable)
  • Table 15.11: Large Volume Wearable Injectors for Insulin: Distribution by Availability of CGM System
  • Table 15.12: Large Volume Wearable Injectors for Insulin: Distribution by Leading Players
  • Table 15.13: Large Volume Wearable Injectors: Distribution by Geography
  • Table 15.14: List of Patents, 2013-2016
  • Table 15.15: Patent Analysis: Distribution by Current Status
  • Table 15.16: Patent Analysis: Distribution by Year
  • Table 15.17: Patent Analysis: Distribution by Key Players
  • Table 15.18: Patent Analysis: Distribution by Regional Approving Authorities
  • Table 15.19: Patent Analysis: Distribution by the Type of Patent
  • Table 15.20: Patent Analysis: Distribution by Patent Expiry Year
  • Table 15.21: Diabetes: Worldwide Distribution of the Patients (2015)
  • Table 15.22: Prevalence of Diabetes: Distribution by Continent (In Million)
  • Table 15.23: Treprostinil IV Formulation: Annual Sales, 2012 - Q1-Q3 2016 (USD Million)
  • Table 15.24: Furosemide IV Formulation: Annual Sales, 2013 - Q1-Q3 2016 (EUR Million)
  • Table 15.25: Herceptin®: Annual Sales, 1999-2015 (CHF Million)
  • Table 15.26: Levodopa / Carbidopa: Annual Sales, 2010-2015 (USD Million)
  • Table 15.27: Apokyn®: Annual Sales, 2011-2015 (USD Million)
  • Table 15.28: Rocephin®: Annual Sales, 2014-2015 (CHF Million)
  • Table 15.29: Large Volume Wearable Injectors Market for Non-Insulin Biologics: Base Scenario, 2017-2027 (USD Million)
  • Table 15.30: Large Volume Wearable Injectors Market for Non-Insulin Biologics: Conservative Scenario, 2017-2027 (USD Million)
  • Table 15.31: Large Volume Wearable Injectors Market for Non-Insulin Biologics: Optimistic Scenario, 2017-2027 (USD Million)
  • Table 15.32: Large Volume Wearable Injectors Market for Non-Insulin Biologics: Base Scenario, Number of Units, 2017-2027 (Million)
  • Table 15.33: Large Volume Wearable Injectors Market for Non-Insulin Biologics: Conservative Scenario, Number of Units, 2017-2027 (Million)
  • Table 15.34: Large Volume Wearable Injectors Market for Non-Insulin Biologics: Optimistic Scenario, Number of Units, 2017-2027 (Million)
  • Table 15.35: Large Volume Wearable Injectors for Non-Insulin Biologics: Market Evolution 2021-2024-2027 (Million)
  • Table 15.36: Large Volume Wearable Injectors for Non-Insulin Biologics: Market Share of Devices, 2016, 2020, 2027 (USD Million)
  • Table 15.37: Large Volume Wearable Injectors Market for Insulin: Base Scenario, 2017-2027 (USD Million)
  • Table 15.38: Large Volume Wearable Injectors Market for Insulin: Base Scenario, Number of Units, 2017-2027 (Million)
  • Table 15.39: Becton Dickinson: Annual Revenues, 2011-2016 (USD Billion)
  • Table 15.40: Insulet Corporation: Annual Revenues, 2011- Q1-Q3 2016 (USD Million)
  • Table 15.41: Roche: Annual Revenues, 2011 - Q1-Q3 2016 (CHF Million)
  • Table 15.42: Roche: Annual Revenues, 2016: Distribution by Business Segment (CHF Billion)
  • Table 15.43: Tandem Diabetes Care: Annual Revenues, 2012 - Q1-Q3 2016 (USD Million)
  • Table 15.44: Unilife Corporation: Annual Revenues, 2011-2016 (USD Million)
  • Table 15.45: West Pharmaceutical Services: Annual Revenues, 2011-2016 (USD Million)
  • Table 15.46: Large Volume Wearable Injectors for Non-Insulin Biologics Market Summary: Number of Units 2017, 2022 and 2027 (Million)

Listed Companies:

The following companies and organizations have been mentioned in the report:

  • 1. 5AM Ventures
  • 2. Abbott Laboratories
  • 3. AbbVie
  • 4. AbGenomics
  • 5. Ablynx
  • 6. Acceleron Pharma
  • 7. Accord Healthcare
  • 8. Aduro Biotech
  • 9. Advaxis
  • 10. Agenus
  • 11. AgonOx
  • 12. Akorn
  • 13. Alder BioPharmaceuticals
  • 14. Alexion Pharmaceuticals
  • 15. Alixinox Pharmaceuticals
  • 16. Alnylam Pharmaceuticals
  • 17. AlphaCore Pharma
  • 18. Altor BioScience
  • 19. Alzheimer's Association
  • 20. American Academy of Neurology
  • 21. American Nurses Association
  • 22. Amgen
  • 23. Amphastar Pharmaceuticals
  • 24. Animas Corporation
  • 25. Antares Pharma
  • 26. Antigen Express
  • 27. Apotex
  • 28. Arbutus Biopharma
  • 29. Argos Therapeutics
  • 30. Arteaus Therapeutics
  • 31. Arthurian Life Sciences
  • 32. ARTORG Center for Biomedical Research
  • 33. Asante Solutions
  • 34. Aspen Pharmacare
  • 35. Astellas Pharma
  • 36. Asthma and Allergy Foundation of America
  • 37. AstraZeneca
  • 38. Athersys
  • 39. Aurum Pharmaceuticals
  • 40. AVEO Oncology
  • 41. Banque
  • 42. Bardy Diagnostics
  • 43. Baxter
  • 44. Bayer
  • 45. Bayhill Therapeutics
  • 46. Becton Dickinson
  • 47. Bespak
  • 48. Bigfoot Biomedical
  • 49. BioArctic Neuroscience
  • 50. bioCSL
  • 51. Biogen
  • 52. BioInvent International
  • 53. Bioject Medical Technologies
  • 54. BioMarin Pharmaceutical
  • 55. Bio-Path Holdings
  • 56. Biotest
  • 57. Boehringer Ingelheim
  • 58. Bristol-Myers Squibb
  • 59. Cala Health
  • 60. Calando Pharmaceuticals
  • 61. Cam Med
  • 62. Canadian Institute for Health Information
  • 63. Canadian Intellectual Property Office
  • 64. Cancer Advances
  • 65. CANÈ
  • 66. Cardiome Pharma
  • 67. Catalyst Biosciences
  • 68. Celgene
  • 69. Celldex Therapeutics
  • 70. Cellerant Therapeutics
  • 71. Cellnovo
  • 72. CEL-SCI Corporation
  • 73. Centers for Disease Control and Prevention
  • 74. CeQur
  • 75. Chugai Pharmaceutical
  • 76. Cincinnati Children's Hospital Medical Center
  • 77. Cipla
  • 78. Circadian Technologies
  • 79. Cleveland BioLabs
  • 80. CONNECT
  • 81. Consort Medical
  • 82. Crealta Pharmaceuticals
  • 83. CROSSJECT
  • 84. CSL Behring
  • 85. CureTech
  • 86. CytoDyn
  • 87. Cytonet
  • 88. Daikyo Seiko
  • 89. Debiotech
  • 90. Deerfield Management Company
  • 91. DEKA
  • 92. Dekkun
  • 93. Denderon
  • 94. Dexcom
  • 95. Diamyd Medical
  • 96. Diasend
  • 97. Bern University Hospital
  • 98. Duke University Medical Center
  • 99. Egalet Corporation
  • 100. Eisai
  • 101. Elan Pharmaceuticals
  • 102. Elcam Drug Delivery Devices
  • 103. Eli Lilly
  • 104. Elias Group
  • 105. Elusys Therapeutics
  • 106. Emcure Pharmaceuticals
  • 107. EMD Serono
  • 108. Emergent BioSolutions
  • 109. Emory University Hospital
  • 110. Enable Injections
  • 111. Endeavour Vision
  • 112. Endo Pharmaceuticals
  • 113. Endocyte
  • 114. Eternity Healthcare
  • 115. European Agency of Occupational Safety and Health
  • 116. European Pharma Group
  • 117. Federated Investors
  • 118. Ferring Pharmaceuticals
  • 119. FibroGen
  • 120. Finox Biotech
  • 121. Five Prime Therapeutics
  • 122. Flex (formerly Flextronix)
  • 123. Flowonix Medical
  • 124. Forma Medical Device Design
  • 125. Fresenius Kabi
  • 126. Galaxy Biotech
  • 127. Galena Biopharma
  • 128. Genentech
  • 129. Generon Corporation (Shanghai)
  • 130. Geno Pharmaceuticals
  • 131. Genzyme Corporation
  • 132. Gilead Sciences
  • 133. Gland Pharma
  • 134. GlaxoSmithKline
  • 135. Gliknik
  • 136. Glooko
  • 137. Halozyme Therapeutics
  • 138. HanAll BioPharma
  • 139. Hanmi Pharmaceutical
  • 140. HealthPrize Technologies
  • 141. Heart Failure Clinical Research Network
  • 142. Heart Failure Society of America
  • 143. Hemispherx Biopharma
  • 144. Hospira
  • 145. ImClone Systems
  • 146. Immatics Biotechnologies
  • 147. Immune Response BioPharma
  • 148. Immunocore
  • 149. ImmunoFrontier
  • 150. ImmunoGen
  • 151. Immunomedics
  • 152. Immunotope
  • 153. Immunovaccine
  • 154. Immunovative Therapies
  • 155. Ind-Swift
  • 156. Ingenus Pharmaceuticals
  • 157. INJEX Pharma
  • 158. Inovio Pharmaceuticals
  • 159. Insulet Corporation
  • 160. Insuline Medical
  • 161. International Diabetes Federation
  • 162. Ionis Pharmaceuticals
  • 163. IP Holdings
  • 164. Ipca Laboratories
  • 165. Ipsen
  • 166. iSense CGM
  • 167. Janssen Biotech
  • 168. Johnson & Johnson
  • 169. Kaléo
  • 170. KaloBios Pharmaceuticals
  • 171. KB Partners
  • 172. Kyowa Hakko Kirin
  • 173. Leading Pharma
  • 174. LifeScan
  • 175. Lundbeckfonden Ventures
  • 176. MabVax Therapeutics
  • 177. MacroGenics
  • 178. Massachusetts General Hospital
  • 179. Mayo Clinic
  • 180. MEDAXOR
  • 181. Medical International Technology
  • 182. Medicom Innovation Partner
  • 183. Medicus Engineering
  • 184. MedImmune
  • 185. Medimop Medical Projects
  • 186. Medipacs
  • 187. Medtronic
  • 188. Medtrum
  • 189. MENTRIK Biotech
  • 190. Merck
  • 191. Meridian Medical Technologies
  • 192. Merrimack Pharmaceuticals
  • 193. Merz Pharma
  • 194. MetroHealth System
  • 195. Mode AGC
  • 196. Modi Mundi Pharma
  • 197. MolMed
  • 198. MorphoSys
  • 199. Morphotek
  • 200. Mylan
  • 201. Bar Ilan University
  • 202. National Institute for Clinical Excellence
  • 203. National Institutes of Health
  • 204. Neogenix Oncology
  • 205. Neon Laboratories
  • 206. NeuroDerm
  • 207. Noble
  • 208. Norwich Pharmaceuticals
  • 209. Novartis
  • 210. Novo Nordisk
  • 211. Nuron Biotech
  • 212. Occupational Safety and Health Administration
  • 213. Octapharma
  • 214. Omeros
  • 215. OncoGenex Pharmaceuticals
  • 216. OncoMed Pharmaceuticals
  • 217. OncoPep
  • 218. Optimer Pharmaceuticals
  • 219. OrbiMed
  • 220. ORI Healthcare Fund
  • 221. Otsuka Pharmaceutical
  • 222. Owen Mumford
  • 223. Peregrine Pharmaceuticals
  • 224. Perqflo
  • 225. Pfizer
  • 226. PharmaJet
  • 227. PhaseBio Pharmaceuticals
  • 228. Pico Life Technologies
  • 229. PicoSulin
  • 230. Pique Therapeutics
  • 231. Pliva
  • 232. Pluristem Therapeutics
  • 233. Polaris Pharmaceuticals
  • 234. Polynoma
  • 235. Portola Pharmaceuticals
  • 236. Prachi Pharmaceuticals
  • 237. Progenics Pharmaceuticals
  • 238. Promethera Biosciences
  • 239. Prometheus Laboratories
  • 240. Protalix BioTherapeutics
  • 241. Qualitest Pharmaceuticals
  • 242. Quest Pharmatech
  • 243. Quintessence Biosciences
  • 244. RAD BioMed
  • 245. Ranbaxy Laboratories
  • 246. Ratio Drug Delivery
  • 247. Regeneron Pharmaceuticals
  • 248. rEVO Biologics
  • 249. Roche
  • 250. Roehr Products
  • 251. Roxane Laboratories
  • 252. Sagent Pharmaceuticals
  • 253. Salix Pharmaceuticals
  • 254. Samson Ventures Partners
  • 255. Sandoz
  • 256. Sangamo BioSciences
  • 257. Sanofi
  • 258. Sarpeta Therapeutics
  • 259. SBIR Healthcare
  • 260. Schroders
  • 261. SciGen
  • 262. scPharmaceuticals
  • 263. Seattle Genetics
  • 264. Sensile Medical
  • 265. Shionogi
  • 266. Shire
  • 267. Sigma-Tau Pharmaceuticals
  • 268. SillaJen BioTherapeutics
  • 269. SOOIL
  • 270. SteadyMed Therapeutics
  • 271. Stemline Therapeutics
  • 272. STMicroelectronics
  • 273. Sun Pharmaceutical Industries
  • 274. Sunovion Pharmaceuticals
  • 275. Syntax Corporation
  • 276. TaiMed Biologics
  • 277. Takeda Pharmaceutical Company
  • 278. Tamir Biotechnology
  • 279. Tandem Diabetes Care
  • 280. Teva Pharmaceutical Industries
  • 281. TG Therapeutics
  • 282. The Tech Group
  • 283. Tidepool
  • 284. Touche Medical
  • 285. TRACON Pharmaceuticals
  • 286. TypeZero Technologies
  • 287. UCB
  • 288. Unilife Corporation
  • 289. United Biomedical
  • 290. United States Patent and Trademark Office
  • 291. United Therapeutics
  • 292. University of Bern
  • 293. US WorldMeds
  • 294. Vaccinex
  • 295. Vaccinogen
  • 296. Valeritas
  • 297. Valtronic
  • 298. VBL Therapeutics
  • 299. VI Partners
  • 300. ViCentra
  • 301. Vintage Pharmaceuticals
  • 302. West Pharmaceutical Services
  • 303. Wockhardt
  • 304. Woodford Investment Management
  • 305. World Intellectual Property Organization
  • 306. XBiotech
  • 307. Xencor
  • 308. XOMA Corporation
  • 309. YOFimeter
  • 310. Ypsomed
Back to Top